Patent application number | Description | Published |
20080269464 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided. | 10-30-2008 |
20100166784 | METHOD AND COMPOSITIONS FOR MODULATING TH17 CELL DEVELOPMENT - The invention encompasses methods and compositions for modulating Th17 development. | 07-01-2010 |
20100310582 | METHODS FOR INDUCING IN VIVO TOLERANCE - The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue. | 12-09-2010 |
20110230647 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 09-22-2011 |
20110236401 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided. | 09-29-2011 |
20120207759 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 08-16-2012 |
20120322986 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided. | 12-20-2012 |
20130034571 | METHODS FOR INDUCING IN VIVO TOLERANCE - The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue. | 02-07-2013 |